Astellas, Seagen seek speedy reviews of Padcev in bladder cancerThe next milestone in Seagen and Astellas’ bid to build their antibody-drug conjugate (ADC) Padcev into a blockbuster Share XAstellas, Seagen seek speedy reviews of Padcev in bladder cancerhttps://pharmaphorum.com/news/astellas-seagen-seek-speedy-reviews-of-padcev-in-bladder-cancer/
Astellas/Seagen prepare full US filing of bladder cancer drug PadcevAstellas and Seagen have the data they need for a full licence for their bladder cancer drug Padcev Share XAstellas/Seagen prepare full US filing of bladder cancer drug Padcevhttps://pharmaphorum.com/news/astellas-seagen-to-prepare-for-full-us-filing-of-bladder-cancer-drug-padcev/
Seagen and Genmab file ‘trojan horse’ drug with FDA for cervical cancerSeagen and Genmab have announced they have filed their antibody-drug conjugate tisotumab vedotin with the FDA for patients Share XSeagen and Genmab file ‘trojan horse’ drug with FDA for cervical cancerhttps://pharmaphorum.com/news/seagen-and-genmab-file-trojan-horse-cancer-drug-with-fda/
MacroGenics’ HER2 breast cancer drug Margenza approved in USMacroGenics’ HER2-targeted breast cancer drug Margenza has been approved by the FDA, challenging several recently approved drugs with Share XMacroGenics’ HER2 breast cancer drug Margenza approved in UShttps://pharmaphorum.com/news/macrogenics-her2-breast-cancer-drug-margenza-approved-in-us/
